P2RX7 inhibitor suppresses exosome secretion and disease phenotype in P301S tau transgenic mice.
Zhi RuanJean-Christophe DelpechSrinidhi Venkatesan KalavaiAlicia A Van EnooJianqiao HuSeiko IkezuTsuneya IkezuPublished in: Molecular neurodegeneration (2020)
The oral administration of P2RX7 inhibition mitigates disease phenotypes in P301S mice, likely by suppressing release of microglial exosomes. P2RX7 could be a novel therapeutic target for the early stage tauopathy development.